Detalhe da pesquisa
1.
Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency.
Immunity
; 46(1): 148-161, 2017 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27986455
2.
A High-Dimensional Atlas of Human T Cell Diversity Reveals Tissue-Specific Trafficking and Cytokine Signatures.
Immunity
; 45(2): 442-56, 2016 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27521270
3.
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
Cancer
; 130(10): 1758-1765, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38422026
4.
Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer.
Hum Genomics
; 17(1): 66, 2023 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37461096
5.
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.
Nature
; 557(7706): 575-579, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29769722
6.
Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency.
Immunity
; 48(5): 1060, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29768165
7.
Correction: Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer.
Hum Genomics
; 17(1): 74, 2023 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37580755
8.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol
; 19(12): 1654-1667, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413378
9.
Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
BMC Cancer
; 18(1): 1288, 2018 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30583726
10.
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
BMC Cancer
; 18(1): 1198, 2018 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30509246
11.
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients.
Pharmacogenet Genomics
; 27(3): 120-123, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28059867
12.
Novel therapeutic targets on the horizon for lung cancer.
Lancet Oncol
; 17(8): e347-e362, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27511159
13.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Lancet Oncol
; 17(5): 577-89, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27083334
14.
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Cancer
; 121(10): 1599-607, 2015 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25639864
15.
Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.
Mol Ther
; 22(1): 132-9, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24297049
16.
Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer.
Mol Cancer
; 13: 13, 2014 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24461128
17.
Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Int J Cancer
; 135(5): 1092-100, 2014 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24482041
18.
Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Eur J Clin Pharmacol
; 70(2): 155-66, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24193570
19.
Oncogene-driven non-small cell lung cancers in patients with a history of smoking lack smoking-induced mutations.
Cancer Res
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587551
20.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Lancet Oncol
; 13(5): 528-38, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22452896